Millennium Management LLC acquired a new position in shares of Nabriva Therapeutics (NASDAQ:NBRV) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 867,613 shares of the biotechnology company’s stock, valued at approximately $5,188,000. Millennium Management LLC owned about 2.36% of Nabriva Therapeutics as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Stanley Laman Group Ltd. bought a new stake in Nabriva Therapeutics during the 4th quarter worth $154,000. Jane Street Group LLC bought a new stake in Nabriva Therapeutics during the 3rd quarter worth $293,000. Cubist Systematic Strategies LLC bought a new stake in Nabriva Therapeutics during the 3rd quarter worth $348,000. Virtu Financial LLC bought a new stake in Nabriva Therapeutics during the 4th quarter worth $429,000. Finally, Goldman Sachs Group Inc. bought a new stake in Nabriva Therapeutics during the 4th quarter worth $637,000. Institutional investors and hedge funds own 55.56% of the company’s stock.
A number of equities research analysts recently weighed in on NBRV shares. Morgan Stanley started coverage on Nabriva Therapeutics in a research report on Wednesday, January 17th. They set an “overweight” rating and a $10.00 price objective on the stock. Cantor Fitzgerald set a $16.00 price objective on Nabriva Therapeutics and gave the stock a “buy” rating in a research report on Friday, March 16th. ValuEngine lowered Nabriva Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Wedbush restated an “outperform” rating on shares of Nabriva Therapeutics in a research report on Monday, March 19th. Finally, Bank of America started coverage on Nabriva Therapeutics in a research report on Wednesday, March 21st. They set a “buy” rating and a $10.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $16.69.
Shares of NBRV opened at $4.90 on Tuesday. The stock has a market cap of $180.28, a price-to-earnings ratio of -1.97 and a beta of 1.76. Nabriva Therapeutics has a 12 month low of $4.39 and a 12 month high of $14.10.
Nabriva Therapeutics (NASDAQ:NBRV) last announced its earnings results on Friday, March 16th. The biotechnology company reported ($0.60) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.06). The company had revenue of $1.12 million for the quarter, compared to analyst estimates of $1.37 million. Nabriva Therapeutics had a negative return on equity of 88.66% and a negative net margin of 1,370.53%. equities analysts anticipate that Nabriva Therapeutics will post -2.18 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Millennium Management LLC Takes $5.19 Million Position in Nabriva Therapeutics (NBRV)” was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.thelincolnianonline.com/2018/04/17/millennium-management-llc-takes-5-19-million-position-in-nabriva-therapeutics-nbrv.html.
Nabriva Therapeutics Profile
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which has completed a Phase II clinical trial for acute bacterial skin and skin structure infections.
Want to see what other hedge funds are holding NBRV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nabriva Therapeutics (NASDAQ:NBRV).
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.